What is Jefferies's price target for INZY?

Jefferies's latest stated price target for Inozyme Pharma Inc. (INZY) is $17, from its action on Aug 13, 2024.

What is Jefferies's rating on INZY?

Jefferies rates INZY Buy, a bullish rating, as of Aug 13, 2024.

When did Jefferies last change its view on INZY?

On Aug 13, 2024, Jefferies resumes coverage at Buy, price target $16 to $17.

Jefferies INZY price target and rating history

Inozyme Pharma Inc. (INZY) · Health Care

Jefferies rates Inozyme Pharma Inc. (INZY) Buy with a $17 price target, as of its latest action on Aug 13, 2024. It has published 3 rating actions on INZY since May 2022, including 1 upgrade and 0 downgrades.

Current rating: Buy
Price target: $17
Median target, all firms: Too few
Actions on INZY: 3

Jefferies price target on INZY

Jefferies price target on INZY, each point a stated target, May 2022 to August 2024.

Every Jefferies rating on INZY

Aug 13, 2024
ResumeJefferies resumes coverage at Buy, price target $16 to $17
Mar 23, 2023
UpgradeJefferies upgrades to Buy from Hold, price target $4.50 to $6
May 26, 2022
InitiateJefferies starts coverage at Hold, price target $5

Questions about Jefferies and INZY

What is Jefferies's price target for INZY?: Jefferies's latest stated price target for Inozyme Pharma Inc. (INZY) is $17, from its action on Aug 13, 2024.
What is Jefferies's rating on INZY?: Jefferies rates INZY Buy, a bullish rating, as of Aug 13, 2024.
When did Jefferies last change its view on INZY?: On Aug 13, 2024, Jefferies resumes coverage at Buy, price target $16 to $17.

All Jefferies ratings INZY news and filings Every analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.